Abzyme’s strong suit is its technology to optimize existing antibodies and develop de novo both traditional and modular antibodies with desired attributes. Abzyme can create virtually a limitless variety of bispecific products depending on the therapeutic need, using our single-domain antibody generation platform.
The Company employs a hybrid business model that includes:
Fee-for-service
- VHH Antibody Discovery/Development
- Screening of Pre-Immunized Llama Libraries of 100+ Therapeutic Targets
- Conditionally-active Antibody Engineering
Codevelopment of VHH Assets
- Solid/Liquid Tumor Targets
- Ophthalmology Targets
- Multiple Sclerosis Targets
Non-exclusive Licensing
- Tumor Activation/Masking Technology
- pH-dependent anti-CD3 scFv
For certain programs, we are currently seeking strategic collaborations to jointly advance antibody development and commercialization.